Table 2.
Donor and Transplant Characteristics
| Variable | Number of Patients | |
|---|---|---|
| Donor age (yrs), range(median) 3.4 – 69.1 (40.1) | ||
| Sex, male/female | 51/34 | |
| Donor/patient CMV status* | ||
| −/− | 21 | |
| −/+ | 26 | |
| +/+ | 25 | |
| +/− | 11 | |
| Donor patient relationship | ||
| –Related | ||
| HLA-identical sibling | 32 | |
| HLA-matched relative other than sibling | 2 | |
| HLA-mismatched relative | 4 | |
| –Unrelated | ||
| HLA-matched | 39 | |
| HLA-mismatched | 8 | |
| Donor / Patient sex | ||
| F / F | 13 | |
| F / M | 21 | |
| M / F | 20 | |
| M / M | 31 | |
| Conditioning regimen | ||
| BU (7 mg/kg)/CY (50 mg/kg)/TBI (12 Gy) | 10 | |
| BU (7 mg/kg)/TBI (12 Gy) | 11 | |
| BU (16 mg/kg)/CY (120 mg/kg)/THY (4.5 mg/kg) | 29 | |
| CY (120 mg/kg)/TBI (14.4 or 13.2 Gy) | 8 | |
| TBI (2–3 Gy) ± FLU (90 mg/m2) | 6 | |
| FLU (120 mg/m2)/BU (16 mg/kg) | 12 | |
| TBI (2 Gy)/iodine 131-anti-CD45 antibody | 6 | |
| FLU (150 mg/m2)/Treosulfan (3×14 g/m2) | 3 | |
| GVHD prophylaxis regimen | ||
| CSP/MTX | 44 | |
| CSP/MMF | 12 | |
| CSP/Other combinations | 6 | |
| FK506/MTX | 20 | |
| FK506/MMF | 3 | |
| Source of Stem Cells | ||
| Marrow | 32 | |
| PBPC | 53 | |
| Cell dose, range (median) | ||
| Marrow | 0.7–7.8 (2.9) × 108/kg | |
| PBPC (CD34+) | 4.0–30.0 (10.9) × 106/kg | |
*
Data missing for two donors.
†
Eight patients (4 conditioned with targeted BU/CY, 4 conditioned with FLU/targeted BU, and one conditioned with CY/TBI) also received anti-thymocyte globuline [ATG]. One patient conditioned with BU/CY was also given amifostine, 340 mg/m2 [29].
Abbreviations: Bu = busulfan; CMV = cytomegalovirus; CSP = cyclosporine; HLA = Human leukocyte antigen; F= female; FK506 = tacrolimus; Flu = fludarabine; M= male; MMF = mycophenolate mofetil; MTX = methotrexate; PBPC = peripheral blood progenitor cells; TBI = total body irradiation